Clinical trial
A Phase Ib Dose Escalation Trial of Carfilzomib in Combination With Bendamustine and Rituximab In Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT02187133 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib Dose Escalation Trial of Carfilzomib in Combination With Bendamustine and Rituximab In Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- Lead sponsor
- University of California, San Francisco
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 5, 2015
- Completion date
- March 31, 2021
- Enrollment
- 10 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.